Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: CVT-301
DRUG: Placebo

Sponsor

Acorda Therapeutics